- Collagen Solutions has announced a supply agreement with Histogenics, a regenerative medicine company focused on developing and commercializing products in the musculoskeletal space.

The supply agreement will encompass additional collagen material sources for use in Histogenics' investigational product candidate, NeoCart, a regenerative medicine product currently in phase 3 clinical trials using autologous cell therapy, biomaterials and engineering to develop a tissue implant to repair knee cartilage damage.

The supply agreement may also encompass additional future products in the Histogenics pipeline for use in markets outside of the United States.

Chief executive Dr Stewart White said: "Collagen Solutions has again demonstrated that it can provide materials which add real value to the delivery of novel regenerative therapies such as NeoCart®, which is a novel product that is synergistic with ChondroMimetic, the product which Collagen Solutions recently acquired. We are very pleased to be part of the Histogenics journey and look forward to participating in an exciting future with Adam and the team in Boston."

At 8:47am: [LON:COS] COLLAGEN SOLUTIONS ORD 1P share price was -0.12p at 12.38p

Story provided by